Cargando…
Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma
Glioblastoma is the most common brain primary malignant tumor with the highest mortality. Boron neutron capture therapy (BNCT) can efficiently kill cancer cells on the cellular scale, with high accuracy, short course and low side-effects, which is regarded as the most promising therapy for malignant...
Autores principales: | Chen, Jiejian, Dai, Qi, Yang, QiYao, Bao, Xiaoyan, Zhou, Yi, Zhong, Haiqing, Wu, Linjie, Wang, Tiantian, Zhang, Zhicheng, Lu, Yiying, Zhang, Zhentao, Lin, Mengting, Han, Min, Wei, Qichun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895533/ https://www.ncbi.nlm.nih.gov/pubmed/35246144 http://dx.doi.org/10.1186/s12951-022-01304-0 |
Ejemplares similares
-
Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy
por: Chen, Jiejian, et al.
Publicado: (2019) -
Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche
por: Zhou, Yi, et al.
Publicado: (2022) -
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy
por: Yang, Qiyao, et al.
Publicado: (2020) -
Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study
por: Kawabata, Shinji, et al.
Publicado: (2021) -
Electrostatic quadrupole DC accelerators for BNCT applications
por: Kwan, J W, et al.
Publicado: (1994)